Edge Therapeutics Inc (NASDAQ:EDGE) CEO Brian A. Leuthner sold 2,500 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $9.94, for a total value of $24,850.00. Following the transaction, the chief executive officer now owns 117,736 shares in the company, valued at $1,170,295.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Edge Therapeutics Inc (EDGE) traded down 1.30% during trading on Friday, reaching $10.59. The company’s stock had a trading volume of 29,511 shares. The company’s 50 day moving average price is $10.60 and its 200 day moving average price is $9.89. The company’s market cap is $326.71 million. Edge Therapeutics Inc has a 52 week low of $7.30 and a 52 week high of $13.50.

Edge Therapeutics (NASDAQ:EDGE) last posted its quarterly earnings data on Tuesday, August 1st. The biotechnology company reported ($0.44) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.44). On average, equities analysts anticipate that Edge Therapeutics Inc will post ($1.87) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Brian A. Leuthner Sells 2,500 Shares of Edge Therapeutics Inc (EDGE) Stock” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/08/brian-a-leuthner-sells-2500-shares-of-edge-therapeutics-inc-edge-stock.html.

Several research firms have weighed in on EDGE. BidaskClub upgraded Edge Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 3rd. Zacks Investment Research lowered Edge Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 3rd.

Hedge funds have recently modified their holdings of the company. Voya Investment Management LLC bought a new stake in shares of Edge Therapeutics in the 2nd quarter valued at about $106,000. Wells Fargo & Company MN raised its holdings in shares of Edge Therapeutics by 1.7% in the 1st quarter. Wells Fargo & Company MN now owns 11,942 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 200 shares during the period. Russell Investments Group Ltd. raised its holdings in shares of Edge Therapeutics by 16.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,959 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 1,733 shares during the period. State of Wisconsin Investment Board bought a new stake in shares of Edge Therapeutics in the 2nd quarter valued at about $154,000. Finally, Trexquant Investment LP bought a new stake in shares of Edge Therapeutics in the 1st quarter valued at about $143,000. 49.38% of the stock is currently owned by institutional investors.

About Edge Therapeutics

Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.

Insider Buying and Selling by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Receive News & Stock Ratings for Edge Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc and related stocks with our FREE daily email newsletter.